Central Nervous System CNS disorders encompass a vast array of diseases, including but not limited to, Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, and Epilepsy. Despite years of research, only limited progress has been made to address these diseases. We at Pier 23 Labs are committed to accelerating clinical research that addresses such disorders, promoting the development of novel treatments, and improving the quality of life of the diseased. In this blog post, we will discuss our novel innovations in clinical trials that we are currently conducting, and how it is driving significant progress in neurological health.
At Pier 23 Labs, we are committed to advancing clinical research that leverages the latest technological innovations to diagnose and manage CNS disorders. Our advanced clinical trials utilize cutting-edge technology and precision medicine approaches to enhance patient outcomes and promote disease recovery. One of our top priority areas is the identification of biomarkers that enable us to better understand the progression of CNS disorders, which, in turn, helps to develop targeted therapies for individuals.
Therefore, we utilize a range of clinical imaging techniques, including magnetic resonance imaging (MRI), positron emission tomography (PET), and electroencephalography (EEG), among others, to track disease progression. By doing so, we can develop treatments that are tailored to the patient’s unique condition, rather than relying on medical approaches potentially unsuited to the individual.
Beyond innovating with clinical technologies, we at Pier 23 Labs have integrated unique research models that expedite drug discovery at an affordable cost for pharmaceutical companies. Our clinical trials have implemented a unique “trial-in-a-box” design that reduces the time and resources required to conduct a clinical research study. Further, we leverage Artificial Intelligence (AI) to identify patients who would benefit from specific study treatments and follow up with them in a personalized manner. By utilizing cutting-edge technologies in the clinical research process, Pier 23 Labs is advancing research and development solutions that are unparalleled within the CNS disorders research field.
One of our major ambitions is to engage clinically untested populations to broaden effective treatment options. Our Diversity and Inclusion program for clinical trials aims to address long-standing disparities in clinical trial enrollment rates. We work with diverse communities to create awareness of the need for clinical trial participation in disease research, under-represented demographics such as the elderly, low-income individuals and those living in rural areas, often excluded from research opportunities are targeted in this program. This approach permits us to field peripheral views, and varied patient populations, increasing clinical trials’ reliability and expanding effective treatment options.
Pier 23 Labs continues to push the boundaries of clinical research and neurology. Our latest clinical trial seeks to create a more comprehensive understanding of CNS disorder mechanisms, leading to the development of more effective patient-specific treatments. As part of this trial, we are leveraging augmented and virtual reality to provide realistic visualizations of the patient’s CNS processes and treatment pathways. With the integration of technology and the centralized role of the patients in mind, we device innovative trends to streamline our clinical study procedures. Such innovations ensure cost-effectiveness, will have a significant positive impact on the development of future treatments, and ultimately lead to positive results for patients.
